← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
O-Ray Pharma, Inc.
Pasadena, CA
$6,305,587
Total funding
7
Grants
Funding over time
peak $998.4K · FY2010–23$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,305,587 · 7
By mechanism
R44$5,661,202 · 3
R43$644,385 · 4
Investigators at O-Ray Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid$886,552
R44 · FY2022 · AI
IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid$879,062
R44 · FY2023 · AI
Sustained Release Inner Ear Delivery of Corticosteroid$839,147
R44 · FY2014 · DC
Prevention of Children's Tympanostomy Tube Otorrhea$634,501
R44 · FY2016 · DC
Prevention of Children's Tympanostomy Tube Otorrhea$567,267
R44 · FY2017 · DC
Sustained Release Inner Ear Delivery of Corticosteroid$535,685
R44 · FY2010 · DC
Sustained Release Inner Ear Delivery of Corticosteroid$535,685
R44 · FY2011 · DC
Sustained Release Inner Ear Delivery of Corticosteroid$498,847
R44 · FY2015 · DC
Prevention of Children's Tympanostomy Tube Otorrhea$284,456
R44 · FY2020 · DC
Inner ear therapeutics for sustained treatment of autoimmune inner ear disease$169,214
R43 · FY2018 · DC
Intratympanic delivery of biologics for treatment of autoimmune inner ear disease$161,422
R43 · FY2015 · DC
Prevention of Children's Tympanostomy Tube Otorrhea$159,277
R43 · FY2014 · DC
Ototoxicity protection with intratympanic steroid implant$154,472
R43 · FY2012 · DC